NervGen Pharma Corp. (NGEN)vsRevolution Medicines Inc (RVMD)
NGEN
NervGen Pharma Corp.
$2.19
+1.16%
HEALTHCARE · Cap: $250.53M
RVMD
Revolution Medicines Inc
$205.11
+0.66%
HEALTHCARE · Cap: $44.44B
Smart Verdict
WallStSmart Research — data-driven comparison
RVMD leads profitability with a 0.0% profit margin vs 0.0%. RVMD earns a higher WallStSmart Score of 24/100 (F).
NGEN
Avoid16
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Conservative balance sheet, low leverage
Areas to Watch
Trading at 18.2x book value
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
Trading at 16.9x book value
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : NGEN
NGEN has a balanced fundamental profile.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : NGEN
The primary concerns for NGEN are Price/Book, Revenue Growth, EPS Growth.
Bear Case : RVMD
The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.
Key Dynamics to Monitor
RVMD carries more volatility with a beta of 1.41 — expect wider price swings.
NGEN is growing revenue faster at 0.0% — sustainability is the question.
NGEN generates stronger free cash flow (-6M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
RVMD scores higher overall (24/100 vs 16/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
NervGen Pharma Corp.
HEALTHCARE · BIOTECHNOLOGY · USA
NervGen Pharma Corp. (NGEN) is an innovative biotechnology company dedicated to addressing critical unmet medical needs in neurodegenerative diseases with its proprietary nerve regeneration technology platform. The company focuses on developing groundbreaking therapeutics that aim to restore nerve function in conditions such as multiple sclerosis and spinal cord injuries. By advancing its clinical trials and expanding its intellectual property portfolio, NervGen is strategically positioned to capitalize on the growing demand for effective neurological treatments, presenting substantial growth potential and value creation opportunities for institutional investors.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?